New vaccine V330 aims to stop stomach bug in its tracks

NCT ID NCT06630117

First seen Nov 03, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This early-stage study tested a new vaccine called V330, designed to protect against norovirus—a highly contagious virus that causes vomiting and diarrhea. Researchers gave the vaccine or a placebo to 245 healthy adults split into younger (18-49) and older (60-79) groups. The main goal was to check safety and see how well the body produces protective antibodies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)

    Glendale, California, 91206, United States

  • QPS-MRA, LLC-Early Phase ( Site 0006)

    South Miami, Florida, 33143, United States

  • Research Centers of America ( Hollywood ) ( Site 0004)

    Hollywood, Florida, 33024, United States

  • Velocity Clinical Research, Hallandale Beach ( Site 0003)

    Hallandale, Florida, 33009, United States

Conditions

Explore the condition pages connected to this study.